Oncology & Cancer

Vandetanib in thyroid cancer: No proof of added benefit

Vandetanib (trade name Caprelsa) has been approved in Germany since February 2012 for adult patients suffering from a particular form of aggressive thyroid cancer. The German Institute for Quality and Efficiency in Health ...

page 2 from 3